Assess for peripheral neuropathy and obtain complete blood cell counts prior to each dose
Do not administer HALAVEN on Day 1 or Day 8 in patients with ≥Grade 3 neutropenia,† ≥Grade 2 thrombocytopenia,‡ or Grade 3/4 nonhematologic toxicities
If a dose has been delayed and toxicities have recovered to a severity of Grade 2 or less, resume at the recommended reduced dose
If a dose has been reduced due to toxicities, do not re-escalate
The median duration of exposure was 2.3 months (range: 21 days to 26 months) for patients receiving HALAVEN1
References: 1. HALAVEN [package insert]. Nutley, NJ: Eisai Inc. 2. National Cancer Institute. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events v3.0. NIH Publication # 03-5410. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Published March 31, 2003. Updated August 9, 2006. Accessed January 15, 2016.